ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company. Co.'s clinical stage product candidates include: ORIC-533, an orally bioavailable small molecule inhibitor of CD73 which playing a role in resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-114, a brain penetrant, orally bioavailable, irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; and ORIC-944, an allosteric inhibitor of polycomb repressive complex 2 via the embryonic ectoderm development subunit. We show 16 historical shares outstanding datapoints in our ORIC shares outstanding history coverage, used to compute ORIC market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ORIC market cap history over the course of time is important for investors
interested in comparing ORIC's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ORIC versus a peer is one thing; comparing
ORIC market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ORIC can fluctuate over the course of history.
With this page we aim to empower investors researching ORIC by allowing them to research the ORIC market cap history. |
Free ORIC Email Alerts:
Video: The Importance of Market Cap
